| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Human serum albumin (HSA) (after deprotection and conjugation). Lys(CO‑C3‑p‑I‑Ph)‑O‑tBu itself is a protected intermediate; it is not directly active. After removal of the tert‑butyl group, the resulting lysine derivative acts as a PK modifier that binds to albumin.
|
|---|---|
| ln Vitro |
Lys(CO‑C3‑p‑I‑Ph)‑O‑tBu is a protected chemical intermediate used in solid‑phase peptide synthesis and conjugation chemistry. Its in vitro activity is not directly measured; instead, it is used as a building block to synthesize PK modifiers and PSMA ligands. After deprotection (removal of the O‑tBu group) and conjugation to PSMA ligands, the final molecule improves the PK properties of PSMA ligands by increasing albumin binding.
|
| ln Vivo |
Not applicable for the protected intermediate. After deprotection and conjugation to PSMA ligands, the final molecule (Lys(CO‑C3‑p‑I‑Ph)‑OMe or similar) shows improved PK properties in vivo.
|
| Enzyme Assay |
A general cell‑free protocol for assessing the utility of Lys(CO‑C3‑p‑I‑Ph)‑O‑tBu in peptide synthesis: The compound is used as a building block in solid‑phase peptide synthesis (SPPS). Fmoc‑Lys(CO‑C3‑p‑I‑Ph)‑O‑tBu is loaded onto a Rink Amide resin. Standard SPPS cycles (Fmoc deprotection with 20% piperidine in DMF, coupling with HBTU/HOBt/DIEA) are used to assemble the peptide sequence. After the full peptide sequence is assembled, the tert‑butyl group is removed by treatment with TFA/TIS/H2O (95:2.5:2.5) for 2‑3 hours at room temperature. The deprotected peptide is cleaved from the resin and purified by preparative HPLC. The purified product is characterized by LC‑MS.
|
| Cell Assay |
A general cellular protocol for a PSMA ligand synthesized using Lys(CO‑C3‑p‑I‑Ph)‑O‑tBu: After deprotection and conjugation to a PSMA ligand, the final molecule is radiolabeled (e.g., with ¹¹¹In or 22⁵Ac). PSMA‑expressing LNCaP cells are seeded in 12‑well plates. Cells are incubated with the radiolabeled ligand for 1‑4 hours at 37degC. Cells are washed with cold PBS, and cell‑associated radioactivity is measured by gamma counter. Internalization is assessed by acid wash. The PK‑modified ligand should show similar or better PSMA binding and internalization compared to the unmodified ligand.
|
| Animal Protocol |
A general animal protocol for PK‑modified PSMA ligands synthesized using Lys(CO‑C3‑p‑I‑Ph)‑O‑tBu: The final radiolabeled ligand is administered IV to NSG mice bearing PSMA‑positive xenografts. Blood and tissue samples are collected at multiple time points up to 96 hours. The PK modifier is expected to increase the plasma half‑life of the ligand and improve tumor‑to‑salivary gland ratios compared to the unmodified ligand.
|
| ADME/Pharmacokinetics |
General PK protocol for a PSMA ligand synthesized from Lys(CO‑C3‑p‑I‑Ph)‑O‑tBu: After deprotection, conjugation, and radiolabeling with ¹¹¹In, the ligand is administered via IV injection to male NSG mice. Blood samples are collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, and 96 hours. Radioactivity in blood is counted by gamma counter. PK parameters (AUC, t½, clearance) are calculated. The modified ligand should have a prolonged circulation time due to albumin binding.
|
| Toxicity/Toxicokinetics |
General toxicity protocol: Not applicable for the protected intermediate. For the final radiolabeled PK‑modified PSMA ligand, acute radiation toxicity is assessed in NSG mice as described for the related compound (see V88645, field 9).
|
| References |
|
| Additional Infomation |
Lys(CO‑C3‑p‑I‑Ph)‑O‑tBu has the molecular formula C21H33IN2O3 and a molecular weight of 488.40 g/mol. The tert‑butyl (O‑tBu) group is an acid‑labile protecting group that is stable under basic conditions used in peptide synthesis (e.g., piperidine/DMF for Fmoc deprotection). It is removed by treatment with trifluoroacetic acid (TFA). The compound is a synthetic intermediate used in the preparation of PK‑modified PSMA ligands for targeted radionuclide therapy of prostate cancer. It is stored at -20degC, protected from light. Not for human use. No specific CAS number is provided; the product is available from chemical suppliers. No specific literature reference for this particular t‑Bu ester intermediate was found in the available data; the biological activity described for V88645 (the methyl ester) applies to the final PK‑modified PSMA ligand.
|
| Molecular Formula |
C20H31IN2O3
|
|---|---|
| Molecular Weight |
474.38
|
| Exact Mass |
474.138
|
| CAS # |
2703051-80-1
|
| PubChem CID |
168105159
|
| Appearance |
ointment
|
| Density |
1.332±0.06 g/cm3(Predicted)
|
| Boiling Point |
558.8±50.0 °C(Predicted)
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
26
|
| Complexity |
429
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(C)OC(=O)[C@H](CCCCNC(=O)CCCC1=CC=C(C=C1)I)N
|
| InChi Key |
BTKQPZFZKRZXTN-KRWDZBQOSA-N
|
| InChi Code |
InChI=1S/C20H31IN2O3/c1-20(2,3)26-19(25)17(22)8-4-5-14-23-18(24)9-6-7-15-10-12-16(21)13-11-15/h10-13,17H,4-9,14,22H2,1-3H3,(H,23,24)/t17-/m0/s1
|
| Chemical Name |
tert-butyl (2S)-2-amino-6-[4-(4-iodophenyl)butanoylamino]hexanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (210.80 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1080 mL | 10.5401 mL | 21.0801 mL | |
| 5 mM | 0.4216 mL | 2.1080 mL | 4.2160 mL | |
| 10 mM | 0.2108 mL | 1.0540 mL | 2.1080 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
